VSIG2
V-set and immunoglobulin domain-containing protein 2
Also known as: CTH, CTXL, VSIG2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96IQ7
- Gene
- VSIG2
- Ensembl
- ENSG00000019102
- Chromosome
- 11
- Canonical length
- 327 aa
- Protein class
- Predicted membrane proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Predicted to be involved in lipid metabolic process. Predicted to be located in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
327 residues, UniProt reviewed canonical sequence.
>Q96IQ7|VSIG2
1 MAELPGPFLC GALLGFLCLS GLAVEVKVPT EPLSTPLGKT AELTCTYSTS VGDSFALEWS
61 FVQPGKPISE SHPILYFTNG HLYPTGSKSK RVSLLQNPPT VGVATLKLTD VHPSDTGTYL
121 CQVNNPPDFY TNGLGLINLT VLVPPSNPLC SQSGQTSVGG STALRCSSSE GAPKPVYNWV
181 RLGTFPTPSP GSMVQDEVSG QLILTNLSLT SSGTYRCVAT NQMGSASCEL TLSVTEPSQG
241 RVAGALIGVL LGVLLLSVAA FCLVRFQKER GKKPKETYGG SDLREDAIAP GISEHTCMRA
301 DSSKGFLERP SSASTVTTTK SKLPMVVLocalizationUniProt · AlphaFold · HPA
Whether an antibody against VSIG2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 1
- Mean surface accessibility (rSASA)
- 0.43
- Highest tissue expression
- 584 nTPM
Expression across tissuesHPA
Tissue
- stomach: 584 nTPM
- rectum: 130 nTPM
- colon: 128 nTPM
- urinary bladder: 79 nTPM
- prostate: 55 nTPM
- lung: 43 nTPM
Single-cell type
- parietal cells: 1,024 nCPM
- foveolar cells: 956 nCPM
- colonocytes: 473 nCPM
- esophageal apical cells: 399 nCPM
- urothelial cells: 371 nCPM
- gastric chief cells: 345 nCPM
Immune cell
- classical monocyte: 1.2 nTPM
- total PBMC: 0.9 nTPM
- T-reg: 0.7 nTPM
- naive CD4 T-cell: 0.6 nTPM
- MAIT T-cell: 0.5 nTPM
- memory CD4 T-cell: 0.5 nTPM
Brain region
- cerebral cortex: 15 nTPM
- basal ganglia: 14 nTPM
- midbrain: 7.9 nTPM
- white matter: 7.3 nTPM
- amygdala: 6.7 nTPM
- thalamus: 6.7 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.1
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.65
- DepMap mean gene effect
- 0.12
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads VSIG2 as an antibody target. Whether an autoantibody or antibody against VSIG2 could matter depends on whether native VSIG2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
VSIG2 is annotated at the cell surface, where native VSIG2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label VSIG2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...